Investor consortium acquires Karolinska Development’s shares in Inhalation Sciences

  • 17 februari, 2017
  • 12:01

On February 13 2017 Karolinska Development AB (KDEV) announced it was divesting its shares in ISAB to a new consortium made up of Råsunda Förvaltning AB, Inhalation Sciences` founder Per Gerde and CEO Fredrik Sjövall. KDEV will retain an economic interest in ISAB through an earn-out agreement.

Råsunda Förvaltning AB is a family owned holding company providing expansion capital to innovative growth companies with international potential. KDev Investments, an investment fund jointly owned by Karolinska Development and Rosetta Capital, retains an economic interest in Inhalation Sciences through an earn-out agreement

Jim Van heusden, CEO of Karolinska Development, says: ”We are continuously evaluating options for our portfolio companies to retain and realize as much value as possible. We are pleased Inhalation Sciences has been successful in attracting Råsunda Förvaltning AB as anew investor, which will support the Company towards future milestones. KDev Investments retains an economic interest through an earn-out agreement, which has the potential to generate future value.”